Pancreatic cancer after surgery is a disease where early immune signals matter enormously, so the venue matters: pre-specified analyses from Elicio Therapeutics’ randomized Phase 2 AMPLIFY-7P trial of ELI-002 7P have been selected for a late-breaking Proffered Paper oral presentation at ESMO 2026. That slot, reserved for data the program committee considers worth interrupting the standard agenda, puts a KRAS-targeted cancer vaccine in front of the oncologists who control adjuvant treatment decisions in resected pancreatic ductal adenocarcinoma.
The context here is complicated. The 144-patient AMPLIFY-7P study did not meet its pre-specified primary endpoint of disease-free survival in the intent-to-treat population. What it did produce were signals in patients with lower residual disease burden after surgery, and those findings are now driving a refined Phase 3 strategy. The ESMO presentation covers new pre-specified analyses, not the post-hoc work, which gives the data a firmer statistical footing than the earlier round of results might have suggested.
ELI-002 7P works through Elicio’s Amphiphile platform, which attaches vaccine components to a lipid tail that routes them directly to lymph nodes rather than dispersing through systemic circulation. The goal is a concentrated, targeted T-cell response against the specific mutant KRAS peptides that drive the majority of pancreatic cancers. That mechanism separates it from broader neoantigen approaches, though the KRAS-vaccine space has other entrants, including Gritstone bio’s off-the-shelf SLATE-KRAS program, and the competition for Phase 3 enrollment and eventual market position will depend on which candidate shows the most durable disease-free survival benefit in a defined patient population.
For trial watchers, the operative question coming out of ESMO is whether the pre-specified subgroup data on residual disease burden holds up with enough statistical clarity to anchor a Phase 3 eligibility criterion. If the effect size in low-burden patients is both large and consistent, Elicio has a defensible path to a registrational study with a narrower, better-defined population. That is the single number to watch when the oral presentation runs.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
